U.S. Markets closed

Achillion Pharmaceuticals, Inc. (ACHN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.320-0.040 (-0.917%)
At close: 4:00PM EDT

4.320 0.00 (0.00%)
After hours: 4:09PM EDT

People also watch
FOLDACADCLDXARRYARIA

Achillion Pharmaceuticals, Inc.

300 George Street
New Haven, CT 06511
United States
203-624-7000
http://www.achillion.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees81

Key Executives

NameTitlePayExercisedAge
Dr. Milind S. Deshpande Ph.D.Chief Exec. Officer, Pres and Director816.45kN/A60
Ms. Mary Kay FentonChief Financial Officer and Exec. VP481.24kN/A53
Mr. Joseph TruittChief Commercial Officer and Exec. VP of Bus. Devel.491.44kN/A52
Dr. David Apelian M.D., Ph.D., MBAChief Medical Officer and Exec. VP658.21kN/A52
Glenn SchulmanExec. Director of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Corporate Governance

Achillion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.